Business Wire

FRISS

29.10.2020 07:58:08 CET | Business Wire | Press release

Share
Grupo Ageas Portugal Selects FRISS To Prevent and Protect Their Customers From Fraud

Grupo Ageas Portugal, serving approximately 1.7 million clients with 1,281 employees and via 2,722 agents, announced today that they have selected FRISS Fraud Detection at Claims in order to streamline their digital claim handling and prevent and protect their customers from fraud.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201028005826/en/

The real-time FRISS solution provides a unique combination of out-of-the-box risk and fraud indicators with powerful AI techniques such as predictive models, network analysis, and text mining. With this flexible and future-proof claims fraud solution, Grupo Ageas Portugal will further drive its digital transformation and safely streamline operations. Its customers can be helped with service beyond insurance, while high risks will be automatically flagged for further investigation.

The FRISS solution is pre-integrated with Duck Creek Claims . In order to provide a seamless experience for their claim adjusters, Grupo Ageas Portugal will be using the Anywhere Enabled Integration for this solution available in Duck Creek’s Content Exchange . Besides delivering fast customer service for the insurer’s clients, this will also limit the amount of false positives, giving employees time to focus on their customers. This is a great example of a technology-driven partnership in innovation.

Sjoerd Smeets, Chief Risk Officer at Grupo Ageas, said: "With the choice of FRISS, we have opted for a company fully dedicated to fraud prevention. During the selection process, they have shown their industry knowledge, good technical solutions, and especially agility. We are confident that with FRISS we will detect more fraud, handle claims faster, and provide higher quality for our customers."

Ariane Braam-Verkoren, Global Alliance Manager at FRISS, added, “In my journey at FRISS to expand our business to many new territories in the world, I’m excited to see so many insurers join our quest for honest insurance. We are proud to have Grupo Ageas on board and to be their partner of choice in the fight against fraud in Portugal.”

“To offer the best in risk and fraud detection to our customers, it was critical for us to align with a partner like FRISS,” said Juan Antonio Costa, Country Manager for Spain & Portugal at Duck Creek Technologies. “Their solution employs ultra-modern technologies like machine learning and AI, and Grupo Ageas Portugal made an excellent choice for their customers and for the efficiency of their organization by rapidly executing this step in their digital transformation.”

FRISS Fraud Detection at Claims will be implemented at Grupo Ageas Portugal’s Motor, Property, WMC (Workers’ Compensation), and Personal Accidents lines of business.

About Grupo Ageas Portugal

Founded in 1824, Ageas is an international insurance group based in Brussels and present in 14 countries in Europe and Asia. Operating in Portugal since 2005, Ageas invests in the country as one of the main markets, where it intends to develop, through strong partnerships and contributing to the development of the country and society through the Ageas Foundation and helping Clients to manage, anticipate and protect yourself against risks and unforeseen circumstances, so that you can live the present and the future with maximum security and serenity. The Ageas Portugal Group's mission is to provide an emotional and relevant experience in people's lives, being a reference partner in insurance and the best workplace for entrepreneurial people. To this end, we have 1,281 Employees and 2,722 Mediators to provide an excellent service to the approximately 1.7 million Customers of the various commercial brands: Ageas Seguros, Ageas Pensões, Médis, Ocidental and Seguro Directo. In order to diversify the business and be close to its customers, the Ageas Portugal Group goes beyond insurance, offering a wide range of services through the Clínica Médis, Kleya, Go Far, Ageas Repara and Mundo Ageas. For more information, you can visit the website , or follow us on Linkedin and Instagram .

About Duck Creek Technologies:

Duck Creek Technologies is a leading provider of core system solutions to the P&C and General insurance industry. By accessing Duck Creek OnDemand , the company’s enterprise Software-as-a-Service solution, insurance carriers are able to navigate uncertainty and capture market opportunities faster than their competitors. Duck Creek’s functionally rich solutions are available on a stand-alone basis or as a full suite , and all are available via Duck Creek OnDemand. For more information, visit www.duckcreek.com .

About FRISS

FRISS is 100% focused on automated fraud and risk detection for P&C insurance companies worldwide. Their AI-powered detection solutions for underwriting, claims and SIU help 175+ insurers grow their business. FRISS detects fraud, mitigates risks and supports digital transformation. Insurers go live within 4 months, realize up to 10 times ROI and 80% increase in straight through processing of policy application and claims. FRISS solutions help lower loss ratios, enable profitable portfolio growth, and improve the customer experience. For more information, please visit www.friss.com or Twitter .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 07:03:00 CEST | Press release

Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and

Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 07:00:00 CEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye